Seroatlas · Human Serome Atlas

LYG2

Lysozyme g-like protein 2

Also known as: LYG2_HUMAN, LYGA2, LYGH

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q86SG7
Gene: LYG2
Ensembl: ENSG00000185674
Chromosome: 2
Canonical length: 212 aa
Protein class: Predicted secreted proteins
Secretome location: Secreted in other tissues

OverviewNCBI Gene

The protein encoded by this gene contains a SLT domain, a protein domain present in bacterial lytic transglycosylase (SLT) and in eukaryotic lysozymes (GEWL). SLT domain catalyzes the cleavage of the beta-1,4-glycosidic bond between N-acetylmuramic acid (MurNAc) and N-acetyglucosamine (GlcNAc). [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

212 residues, UniProt reviewed canonical sequence.

>Q86SG7|LYG2
     1  MLSSVVFWGL IALIGTSRGS YPFSHSMKPH LHPRLYHGCY GDIMTMKTSG ATCDANSVMN
    61  CGIRGSEMFA EMDLRAIKPY QTLIKEVGQR HCVDPAVIAA IISRESHGGS VLQDGWDHRG
   121  LKFGLMQLDK QTYHPVGAWD SKEHLSQATG ILTERIKAIQ KKFPTWSVAQ HLKGGLSAFK
   181  SGIEAIATPS DIDNDFVNDI IARAKFYKRQ SF

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LYG2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.32
Highest tissue expression: 7.9 nTPM

Expression across tissuesHPA

Tissue

skin: 7.9 nTPM
retina: 3.2 nTPM
testis: 1.3 nTPM
basal ganglia: 0.4 nTPM
bone marrow: 0.4 nTPM
cerebellum: 0.4 nTPM

Single-cell type

cardiomyocytes: 38 nCPM
retinal ganglion cells: 35 nCPM
retinal horizontal cells: 24 nCPM
rod photoreceptor cells: 23 nCPM
myonuclei: 17 nCPM
epicardial cells: 16 nCPM

Immune cell

naive B-cell: 1.1 nTPM
plasmacytoid DC: 0.9 nTPM
memory CD4 T-cell: 0.8 nTPM
memory B-cell: 0.6 nTPM
memory CD8 T-cell: 0.4 nTPM
gdT-cell: 0.3 nTPM

Brain region

cerebellum: 16 nTPM
cerebral cortex: 8.7 nTPM
white matter: 8.1 nTPM
hypothalamus: 7.3 nTPM
basal ganglia: 7.2 nTPM
hippocampal formation: 7 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.83
gnomAD pLI: 0
gnomAD missense Z: 0.4
DepMap mean gene effect: -0.02
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

lysozyme activity

Cellular components

extracellular region

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LYG2 as an antibody target. Whether an autoantibody or antibody against LYG2 could matter depends on whether native LYG2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LYG2 is annotated as secreted, so native LYG2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label LYG2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...